<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414100</url>
  </required_header>
  <id_info>
    <org_study_id>13C.628</org_study_id>
    <secondary_id>2013-077</secondary_id>
    <nct_id>NCT02414100</nct_id>
  </id_info>
  <brief_title>Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy</brief_title>
  <official_title>Generation of Patient Derived Pancreatic Cancer Cell Lines to Determine Mechanisms of Chemoresistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot research trial studies patient derived cancer cell lines in identifying molecular
      changes in patients with previously untreated pancreatic cancer and are receiving
      gemcitabine hydrochloride-based chemotherapy. Cell lines refer to samples taken from the
      patient's tumor to grow for many months or years in a laboratory, and can therefore be
      studied scientifically. Studying cell lines in the laboratory may help doctors understand
      the genetic changes that occur to the tumor during chemotherapy that allows the tumor to
      resist or grow despite treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the genetic profile of the tumor after progression has occurred, to the tumor
      prior to treatment.

      SECONDARY OBJECTIVES:

      I. Additional molecular patterns, beyond genetics, will be analyzed, including ribonucleic
      acid (RNA) and protein expression.

      OUTLINE:

      Tissue and blood samples are collected for genetic analysis via sequencing from patients
      receiving gemcitabine hydrochloride intravenously or gemcitabine hydrochloride and
      paclitaxel albumin-stabilized nanoparticle formulation. Chemotherapy is not part of the
      protocol. Per standard of care, patients receive gemcitabine hydrochloride (IV) the first 3
      of 4 weeks (qw 3/4 wk) or gemcitabine hydrochloride and paclitaxel albumin-stabilized
      nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genomic profiles of post-treatment samples with acquired resistance against pre-treatment and germline controls</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>This method includes a preprocessing step to filter out unreliable reads, a statistical classification step to identify point mutations that differ from both the reference genome hg19 and the control sample at controlled false-positive rate, and a post-processing step to eliminate platform-specific artifacts inherent in next generation sequencing. ANNOVAR software will then be used to analyze candidate point mutations for their predicted impact on protein function, which will be used to select and prioritize specific mutations for validation and/or further study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of germline mutations in known cancer genes from whole blood genomic deoxyribonucleic acid, and somatic mutations in conditionally reprogrammed cells derived from pre-treatment and post-treatment (e.g., resistant) tumors</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The study will be considered a positive study if in any of the patients' samples, unique mutations are identified in the post-treatment derived cell lines that are not present in the pre-treatment derived cell lines from the same patient.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <condition>Stage IA Pancreatic Cancer</condition>
  <condition>Stage IB Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Patient derived cancer cell lines</arm_group_label>
    <description>Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Patient derived cancer cell lines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cytology Specimen Collection Procedure</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Patient derived cancer cell lines</arm_group_label>
    <other_name>Cytologic Sampling</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with treatment naive pancreatic ductal adenocarcinoma (PDA) treated at Thomas
        Jefferson University or Georgetown University
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected or confirmed pancreatic adenocarcinoma, any stage

          2. &gt;18 years of age

          3. No prior systemic chemotherapy for pancreatic cancer, or currently undergoing
             first-line treatment for pancreatic cancer, or completed only first-line treatment
             for pancreatic cancer

          4. A plan to undergo gemcitabine-based chemotherapy at Thomas Jefferson or a
             collaborating institution

          5. Abdominal/pelvic CT scan or MRI within 4 months of the study

          6. Signed study-specific informed consent

        Exclusion Criteria:

          1. Pregnancy

          2. Prior systemic chemotherapy for pancreatic cancer

          3. Gender/Minority/Pediatric Inclusion for Research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan Winter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordan Winter, MD</last_name>
    <phone>215-955-9402</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pancreas, Biliary and Related Cancer Center</last_name>
    <phone>215-955-9402</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Winter, MD</last_name>
      <phone>215-955-9402</phone>
    </contact>
    <contact_backup>
      <last_name>Pancreas, Biliary and Related Cancer Center</last_name>
      <phone>215-955-9402</phone>
    </contact_backup>
    <investigator>
      <last_name>Jordan Winter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Yeo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Brody, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harish Lavu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy Lewis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashwin Sama, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Brus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edith Mitchell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kowalski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Loren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ali Siddiqui, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colette Shaw, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Shamimi-Noori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Fortina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianqing Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandeep Deshmukh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Yeo, PhD, MPH, MSN, AOCNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shawnna Cannaday, MSN, APN, FNP-BC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleanor Vanderklok, MSN, CRNP, AOCNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Markham, DNP, CRNP, AOCN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Londin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Jefferson University Hospitals</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 18, 2016</lastchanged_date>
  <firstreceived_date>March 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
